This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 ETF Picks for October
by Sanghamitra Saha
A few ETF choices for the month of October.
Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation
by Arpita Dutt
Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.
Here's Why Bluebird Bio (BLUE) Stock Is Falling Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.
Merck Drops Two HCV Combination Programs Amid Competition
by Zacks Equity Research
Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.
How Will Trump's Proposed Tax Reform Impact Drug Companies?
by Zacks Equity Research
Donald Trump has proposed new tax reforms for individuals and corporates. Let's see how the reforms, if passed, will impact pharma companies.
Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China
by Zacks Equity Research
Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.
Intercept (ICPT) Provides Safety Guidelines For Ocaliva
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) provided a statement on the recent safety and dosing issues for lead drug Ocaliva and reinforced that the recommended dosing is safe.
Kite Pharma Triples So Far in 2017: What's Driving the Rally?
by Zacks Equity Research
Kite Pharma's (KITE) shares have surged 300% so far this year riding on the progress of its CAR-T therapy candidate and a favorable buyout offer from Gilead.
Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues
by Arpita Dutt
Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.
Gilead's (GILD) Epclusa Receives Label Expansion in Canada
by Zacks Equity Research
Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid
by Zacks Equity Research
Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.
Should Value Investors Consider Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.
4 Biotech Stocks That Show Promise on Sustainable Growth
by Zacks Equity Research
Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.
Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock
by Zacks Equity Research
Gilead Sciences (GILD) needs Investors to pay close attention to the stock based on moves in the options market lately.
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
by Zacks Equity Research
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger
5 Top-Ranked Biotech Stocks to Buy Right Now
by Arpita Dutt
If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).
Top Ranked Income Stocks to Buy for September 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 8th:
Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus
by Zacks Equity Research
With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.
Mallinckrodt Down as District Court Invalidates Inomax Patents
by Zacks Equity Research
Shares of Mallinckrodt plc (MNK) were down 12.3% after a U.S. District Court invalidated 11 patents covering its second-largest product Inomax.
Buy These 5 Large Caps on Extraordinary ROI Potential
by Zacks Equity Research
Amid heightening tensions in the Korean Peninsula and hurricanes back home, let's take the safer route and invest for the long haul, using ROI as a barometer.
4 Biotech Stocks to Improve Your Portfolio's Health
by Zacks Equity Research
The biotech industry has posted a turnaround in the first half of the year, despite facing pricing issues in 2016.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences
Biotech Stocks Back in Favor: Will the Rally Continue?
by Arpita Dutt
Interest in the biotech sector has picked up with the Gilead (GILD)-Kite acquisition announcement. Will the rally continue?
Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?
by Zacks Equity Research
Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services and woes do not end.